home / stock / nbix / nbix short
Short Information | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,162,036 |
Total Actual Volume | 16,283,647 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 108,102 |
Average Short Percentage | 14.41% |
Is there a NBIX Short Squeeze or Breakout about to happen?
See the NBIX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $138.12 | $138.23 | $139.03 | $137.356 | 410,987 | 69,777 | 16.98% |
07-02-2024 | $138.8 | $137.49 | $139.08 | $136.9156 | 728,722 | 160,377 | 22.01% |
07-01-2024 | $138.11 | $140.11 | $141.665 | $137.63 | 801,922 | 138,963 | 17.33% |
06-28-2024 | $135.02 | $137.67 | $139.34 | $134.955 | 1,531,874 | 182,754 | 11.93% |
06-27-2024 | $136.17 | $134.31 | $136.55 | $134.03 | 889,349 | 104,208 | 11.72% |
06-26-2024 | $134.84 | $135.83 | $136.56 | $132.62 | 616,809 | 114,396 | 18.55% |
06-25-2024 | $133.62 | $135.08 | $136 | $133.62 | 915,290 | 147,029 | 16.06% |
06-24-2024 | $134.88 | $133.62 | $135.52 | $133.41 | 770,692 | 71,200 | 9.24% |
06-21-2024 | $135.02 | $134.57 | $135.64 | $133.36 | 2,204,933 | 145,785 | 6.61% |
06-20-2024 | $130.21 | $134.07 | $135.19 | $129.33 | 988,706 | 152,790 | 15.45% |
06-18-2024 | $135.82 | $130.86 | $136.5 | $130.63 | 1,013,019 | 77,853 | 7.69% |
06-17-2024 | $135.22 | $135.29 | $136.865 | $134.45 | 546,928 | 82,872 | 15.15% |
06-14-2024 | $135.54 | $135.45 | $136.05 | $134.06 | 432,800 | 60,501 | 13.98% |
06-13-2024 | $134.18 | $136.26 | $137.64 | $134.18 | 583,890 | 108,959 | 18.66% |
06-12-2024 | $135.19 | $134.62 | $137.1 | $133.33 | 653,069 | 89,366 | 13.68% |
06-11-2024 | $134.28 | $133.15 | $134.28 | $131.64 | 550,788 | 68,477 | 12.43% |
06-10-2024 | $134.37 | $134.7 | $135.3199 | $132.53 | 475,816 | 78,098 | 16.41% |
06-07-2024 | $133.49 | $134.97 | $136.25 | $132.28 | 496,138 | 89,938 | 18.13% |
06-06-2024 | $133.69 | $133.07 | $133.855 | $130.98 | 892,749 | 115,258 | 12.91% |
06-05-2024 | $133.71 | $133.69 | $137.09 | $133.27 | 779,166 | 103,435 | 13.28% |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH PR Newswire PDUFA Target Action Dates in Late December 2024 Highly Selective CRF 1 Antagonist is the Potent...
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Bios...
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire - CAHtalyst™ Pediatr...